R&D Execs Continue Global Search for Open Innovation
The FierceBiotech website reports that throughout 2011 there’s been a continuation of an intense reengineering of the development process at a slate of Big Pharma companies. Many of the Big Pharma companies have been pushing to reboot their own R&D programs. Perhaps the most exciting change of all–at least for scientists in the field–has been a growing demand for open innovation networks.
Click here to read the full article.